Butyl acrylate

Acute Toxicity: other routes

Administrative data

Endpoint:

acute toxicity: other routes

Type of information:

experimental study

Adequacy of study:

supporting study

Reliability:

2 (reliable with restrictions)

Rationale for reliability incl. deficiencies:

other: Basic data given: study report which meets basic scientific principles

Data source

Reference

Reference Type:

study report

Title:

Unnamed

Year:

1958

Report date:

1958

Materials and methods

Principles of method if other than guideline:

BASF test:
Eight groups of 5 - 10 mice per dose were treated intraperitoneally with preparations of the test substance in 1 and 10 % aqueous traganth, respectively. Group-wise documentation of clinical signs was performed over the 7-day study period. Body weight was determined before the start of the study only, as it was needed for determination of dose. The clinical signs and findings were reported in summary form. On the basis of the observed lethality, the LD50 value was estimated or determined using a graphical evaluation of the dose response curve on probability paper.

GLP compliance:

no

Limit test:

no

Test material

Test material information

Constituent 1

Reference substance name:

Butyl acrylate

EC Number:

205-480-7

EC Name:

Butyl acrylate

Cas Number:

141-32-2

Molecular formula:

C7H12O2

IUPAC Name:

butyl prop-2-enoate

Test material form:

other: liquid

Test animals

Species:

mouse

Strain:

not specified

Sex:

not specified

Details on test animals or test system and environmental conditions:

TEST ANIMALS
- Source: Roessling

Administration / exposure

Route of administration:

intraperitoneal

Vehicle:

other: 1and 10 % aqueous emulsion with traganth

Doses:

79, 126, 204, 316, 501, 794, 1260 and 2040 ml/kg bw (corresponding to 71, 113, 183, 284, 450, 713, 1131 and 1832 mg/kg bw). The 3 highest doses were administered with 10% traganth and rest with 1% traganth. Calculation to mg/kg bw based on density of the test substance (0.9 g/ml).

No. of animals per sex per dose:

5-10

Control animals:

no

Details on study design:

- Duration of observation period following administration: 7 days
- Frequency of observations: after 1 h, 24 h, 48 h, and 7 d
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs

Statistics:

LD50 was calculated according to Wilcoxon

Results and discussion

Effect levels

Effect levels 1

Sex:

not specified

Dose descriptor:

LD50

Effect level:

180 mg/kg bw

95% CL:

133 - 248

Remarks on result:

other: 7 days observation period

Effect levels 2

Sex:

not specified

Dose descriptor:

LD50

Effect level:

4 450 mg/kg bw

Remarks on result:

other: 24 h observation period

Mortality:

The mortalities observed in 7 days were 0/10, 4/10, 6/10, 5/10, 5/5, 5/5, 5,5 and 5/5 in the 71, 113, 183, 284, 450, 713, 1131 and 1832 mg/kg bw dose groups, respectively. The mortalities observed in 24 h were 0/10, 0/10, 3/10, 2/10, 2/5, 4/5, 3,5 and 5/5 in the 71, 113, 183, 284, 450, 713, 1131 and 1832 mg/kg bw dose groups, respectively.

Clinical signs:

In the dose groups 79-204 ml/kg bw, animals were quieter than normal, no other symptoms were observed on the day of administration. Next morning, scrubby fur and sticky eyes were noted. In 316 ml/kg bw dose group, scrubby fur and fast breathing were observed on the day of administration. Next morning, scrubby fur, slight abdominal position in some animals and sticky eyes were noted. In 501 ml/kg bw dose group, scrubby fur, slight staggering and fast breathing were observed on the day of administration. Next morning, scrubby fur was noted. In the dose groups 794-1260 ml/kg bw, animals were quieter than normal, scrubby fur was also observed. In the 2040 ml/kg bw dose group, scrubby fur, staggering, slight abdominal position and intermittent respiration.